Jüergen Wolf, MD, discusses data the phase 2 GEOMETRY mono-1 trial with capmatinib (Tabrecta) in patients with METex14-mutated or high MET amplified advanced non–small cell lung cancer.
Jüergen Wolf, MD, medical director of the Center for Integrated Oncology and professor of Interdisciplinary Translational Oncology at University Hospital of Cologne, discusses data the phase 2 GEOMETRY mono-1 trial with capmatinib (Tabrecta) in patients with METex14-mutated or high MET amplified advanced non—small cell lung cancer (NSCLC).
At the 2020 ASCO Virtual Scientific Program, data from 2 cohorts of the trial, says Wolf. Cohort 6 was a confirmatory cohort. Investigators saw the preplanned statistical hypothesis which involved treating more patients with either high-level MET amplification or METex14 mutation whose disease progressed on 1 prior line of systemic therapy.
In 31 patients with a METex14-skipping mutation, the overall response rate with capmatinib was 48.4%; this confirms what had been reported last year. The same held true with progression-free survival, which was around 8.11 months in that cohort. While these are confirmatory results, they show true efficacy reported with the agent. Promising data have already led to the FDA approval of the drug in this patient population, concludes Wolf.